Home » Stocks » ALBO

Albireo Pharma, Inc. (ALBO)

Stock Price: $29.31 USD -0.07 (-0.24%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $29.55 +0.24 (0.82%) Jul 29, 7:32 PM
Market Cap 563.94M
Revenue (ttm) 8.73M
Net Income (ttm) -119.88M
Shares Out 19.13M
EPS (ttm) -6.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $29.31
Previous Close $29.38
Change ($) -0.07
Change (%) -0.24%
Day's Open 29.57
Day's Range 28.60 - 30.25
Day's Volume 208,552
52-Week Range 22.78 - 49.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.

1 week ago - Zacks Investment Research

Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat pruritus in all subtypes of progressive familial...

1 week ago - Benzinga

– Only once-daily drug indicated for the treatment of pruritus in PFIC –

1 week ago - GlobeNewsWire

– Only once-daily drug indicated for the treatment of pruritus in PFIC –

1 week ago - GlobeNewsWire

Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.

1 week ago - Zacks Investment Research

The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic cholestasis (PFIC).  Bylvay is a potent, non-syste...

1 week ago - Benzinga

– First approval in the world of Bylvay for the treatment of PFIC –

1 week ago - GlobeNewsWire

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Ex...

3 weeks ago - GlobeNewsWire

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Ex...

1 month ago - GlobeNewsWire

Albireo Pharma Inc (NASDAQ: ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization of A3907 in adult liver disease. Data will be...

1 month ago - Benzinga

– Bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters –

1 month ago - GlobeNewsWire

– Phase 3 data presentations on long-term treatment and substantial clinical benefits of Bylvay™ (odevixibat) –

1 month ago - GlobeNewsWire

– Data being presented show long-term benefits of Bylvay in children with PFIC –

1 month ago - GlobeNewsWire

ALBO, EBMT, GAN, IRTC, and WLKP have been added to the Zacks Rank #5 (Strong Sell) List on May 26, 2021

Other stocks mentioned: EBMT, GAN, IRTC, WLKP
2 months ago - Zacks Investment Research

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Exe...

2 months ago - GlobeNewsWire

European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for the tr...

2 months ago - Benzinga

– Bylvay has the potential to become first approved drug to treat all forms of PFIC –

2 months ago - GlobeNewsWire

ALBO, BFIN, GOOS, DKNG, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2021

Other stocks mentioned: BFIN, DKNG, GOOS, LLY
2 months ago - Zacks Investment Research

- PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC -

2 months ago - GlobeNewsWire

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement s...

2 months ago - GlobeNewsWire

ALBIREO PHARMA (ALBO) delivered earnings and revenue surprises of -33.14% and -25.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

– Bylvay TM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU–

2 months ago - GlobeNewsWire

Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET

3 months ago - GlobeNewsWire

– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs –

3 months ago - GlobeNewsWire

BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the up...

3 months ago - GlobeNewsWire

– Dosed first patients in Phase 1 study with new product candidate A3907 –

4 months ago - GlobeNewsWire

– Calls to unite global communities affected by rare diseases –

5 months ago - GlobeNewsWire

– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch –

5 months ago - GlobeNewsWire

BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participation ...

5 months ago - GlobeNewsWire

Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET

5 months ago - GlobeNewsWire

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement ...

5 months ago - GlobeNewsWire

– Company outlining large global rare cholestatic liver disease opportunity –

5 months ago - GlobeNewsWire

Albireo Pharma is developing its lead product candidate Odevixibat for multiple pediatric liver disease indications. The approval of Odevixibat for Progressive Familial Intrahepatic Cholestasis (PFIC) i...

6 months ago - Seeking Alpha

Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases Albireo supports the Alagille syndrome community to advocat...

6 months ago - GlobeNewsWire

BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement ...

6 months ago - GlobeNewsWire

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virt...

6 months ago - GlobeNewsWire

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement ...

6 months ago - GlobeNewsWire

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of...

7 months ago - GlobeNewsWire

- Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients -

7 months ago - GlobeNewsWire

- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus -

8 months ago - GlobeNewsWire

- P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 -

8 months ago - GlobeNewsWire

- Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases-

9 months ago - GlobeNewsWire

Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases Albireo stands together with the PFIC community to h...

9 months ago - GlobeNewsWire

BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of...

9 months ago - GlobeNewsWire

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the prici...

10 months ago - GlobeNewsWire

BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it h...

10 months ago - GlobeNewsWire

Albireo Pharma (ALBO) is in the news Tuesday after positive results from a recent clinical trial sent ALBO stock soaring higher. The post Albireo Pharma News: Why ALBO Stock Is Soaring 45% Today appeare...

10 months ago - InvestorPlace

The company reported positive data from a clinical trial.

10 months ago - The Motley Fool

-Highly statistically significant reductions in both pruritus and serum bile acids-

10 months ago - GlobeNewsWire

— Conference call and webcast to be held at 8:30 a.m. EDT — — Conference call and webcast to be held at 8:30 a.m. EDT —

10 months ago - GlobeNewsWire

About ALBO

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also d... [Read more...]

Industry
Biotechnology
CEO
Ronald Cooper
Employees
90
Stock Exchange
NASDAQ
Ticker Symbol
ALBO
Full Company Profile

Financial Performance

In 2020, Albireo Pharma's revenue was $8.31 million, a decrease of -13.78% compared to the previous year's $9.64 million. Losses were -$107.63 million, 71.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Albireo Pharma stock is "Strong Buy." The 12-month stock price forecast is 73.43, which is an increase of 150.53% from the latest price.

Price Target
$73.43
(150.53% upside)
Analyst Consensus: Strong Buy